248 related articles for article (PubMed ID: 18308215)
1. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
[TBL] [Abstract][Full Text] [Related]
2. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.
Kang CM; Chung YE; Park JY; Sung JS; Hwang HK; Choi HJ; Kim H; Song SY; Lee WJ
J Gastrointest Surg; 2012 Mar; 16(3):509-17. PubMed ID: 22183861
[TBL] [Abstract][Full Text] [Related]
3. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma.
Terai T; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Sho M
Pancreatology; 2023 Dec; 23(8):970-977. PubMed ID: 37914628
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets.
Casadei R; Di Marco M; Ricci C; Santini D; Serra C; Calculli L; D'Ambra M; Guido A; Morselli-Labate AM; Minni F
J Gastrointest Surg; 2015 Oct; 19(10):1802-12. PubMed ID: 26224039
[TBL] [Abstract][Full Text] [Related]
5. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy.
Onkendi EO; Boostrom SY; Sarr MG; Farnell MB; Nagorney DM; Donohue JH; Kendrick ML; Lombardo KM; Haddock MG; Que FG
J Gastrointest Surg; 2012 Feb; 16(2):320-4. PubMed ID: 21956430
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer.
Laurence JM; Tran PD; Morarji K; Eslick GD; Lam VW; Sandroussi C
J Gastrointest Surg; 2011 Nov; 15(11):2059-69. PubMed ID: 21913045
[TBL] [Abstract][Full Text] [Related]
8. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Katz MH; Pisters PW; Evans DB; Sun CC; Lee JE; Fleming JB; Vauthey JN; Abdalla EK; Crane CH; Wolff RA; Varadhachary GR; Hwang RF
J Am Coll Surg; 2008 May; 206(5):833-46; discussion 846-8. PubMed ID: 18471707
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy for pancreatic cancer.
Lowy AM
J Gastrointest Surg; 2008 Sep; 12(9):1600-8. PubMed ID: 18259825
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why?
Maxwell JE; Katz MHG
J Gastrointest Surg; 2021 Mar; 25(3):843-848. PubMed ID: 33205307
[TBL] [Abstract][Full Text] [Related]
11. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis.
Abramson MA; Swanson EW; Whang EE
J Gastrointest Surg; 2009 Jan; 13(1):26-34. PubMed ID: 18946644
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.
Dhir M; Malhotra GK; Sohal DPS; Hein NA; Smith LM; O'Reilly EM; Bahary N; Are C
World J Surg Oncol; 2017 Oct; 15(1):183. PubMed ID: 29017581
[TBL] [Abstract][Full Text] [Related]
13. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?
Cooper AB; Parmar AD; Riall TS; Hall BL; Katz MH; Aloia TA; Pitt HA
J Gastrointest Surg; 2015 Jan; 19(1):80-6; discussion 86-7. PubMed ID: 25091851
[TBL] [Abstract][Full Text] [Related]
14. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?
Barnes CA; Krepline AN; Aldakkak M; Clarke CN; Christians KK; Khan AH; Hunt BC; Ritch PS; George B; Hall WA; Erickson BA; Evans DB; Tsai S
J Gastrointest Surg; 2017 Nov; 21(11):1793-1803. PubMed ID: 28849366
[TBL] [Abstract][Full Text] [Related]
15. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy in pancreatic adenocarcinoma.
de la Pinta C
Hepatobiliary Pancreat Dis Int; 2024 Feb; 23(1):14-19. PubMed ID: 36990839
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy.
Hsieh MC; Chang WW; Yu HH; Lu CY; Chang CL; Chow JM; Chen SU; Cheng Y; Wu SY
Cancer Med; 2018 Jun; 7(6):2328-2338. PubMed ID: 29665327
[TBL] [Abstract][Full Text] [Related]
18. Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer.
Martin RCG; Schoen EC; Philips P; Egger ME; McMasters KM; Scoggins CR
Surgery; 2023 Mar; 173(3):581-589. PubMed ID: 36216618
[TBL] [Abstract][Full Text] [Related]
19. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Underwood PW; Cloyd JM
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38568860
[No Abstract] [Full Text] [Related]
20. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer.
Rajamanickam ES; Christians KK; Aldakkak M; Krepline AN; Ritch PS; George B; Erickson BA; Foley WD; Aburajab M; Evans DB; Tsai S
J Gastrointest Surg; 2017 Mar; 21(3):496-505. PubMed ID: 27896658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
